UroGen Pharma to Present at the TD Cowen 46th Annual Health Care Conference Feb 24, 2026 04:05PM
UroGen Pharma to Report Fourth Quarter and Full-Year 2025 Financial Results on Monday, March 2, 2026 Feb 23, 2026 08:00AM
UroGen Pharma to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit Feb 4, 2026 08:00AM
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Dec 5, 2025 08:00AM
UroGen Pharma to Present at Guggenheim Securities Healthcare Innovation Conference Nov 4, 2025 08:00AM
View Older Stories

Oct 30, 2025 08:00AM UroGen Pharma to Report Third Quarter 2025 Financial Results on Thursday, November 6th, 2025
Oct 2, 2025 08:02AM UroGen publishes clinical review of ZUSDURI for bladder cancer treatment
Oct 2, 2025 08:00AM ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non–Muscle Invasive Bladder Cancer
Sep 8, 2025 08:00AM UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 21, 2025 08:00AM UroGen Pharma to Present at Upcoming Investor Conferences
Aug 5, 2025 08:00AM UroGen reports 72% response durability for bladder cancer drug
Aug 5, 2025 08:00AM UroGen Announces 24-Month Duration of Response of 72.2% from the Pivotal Phase 3 ENVISION Trial of ZUSDURI, the First and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non-Muscl
Jun 15, 2025 10:41PM ROSEN, HIGHLY REGARDED INVESTOR COUNSEL, Encourages UroGen Pharma Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - URGN
Jun 13, 2025 03:10PM ROSEN, SKILLED INVESTOR COUNSEL, Encourages UroGen Pharma Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - URGN
Jun 11, 2025 04:03PM ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages UroGen Pharma Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - URGN
Jun 8, 2025 07:03AM ROSEN, A RANKED AND LEADING LAW FIRM, Encourages UroGen Pharma Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - URGN
Jun 6, 2025 08:00AM UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 2, 2025 11:00AM UroGen Presents uTRACT Registry at ASCO 2025 Annual Meeting Designed to Study Real-World Use of JELMYTO in Low-Grade Upper Tract Urothelial Cancer
Jun 2, 2025 10:01AM UroGen Pharma (URGN) Announces Data at ASCO 2025 Annual Meeting on UGN-102
Jun 2, 2025 10:00AM UroGen Announces Data at ASCO 2025 Annual Meeting on UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
May 27, 2025 04:00PM UroGen Pharma to Present at TD Cowen: 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA
May 21, 2025 12:18PM UroGen Pharma (URGN): FDA ODAC voted 4 to 5 that benefit/risk of UGN-102 for intravesical solution was favorable for treatment of recurrent LG-IR-NMIBC
May 21, 2025 12:17PM UroGen Announces Outcome of Oncologic Drugs Advisory Committee for UGN-102 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
May 12, 2025 08:00AM UroGen Pharma Reports First Quarter 2025 Financial Results and Provides a Business Update
May 7, 2025 08:57AM UroGen Pharma (URGN) Announces FDA Advisory Committee for UGN-102
May 7, 2025 08:57AM UroGen Announces FDA Advisory Committee for UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
May 1, 2025 04:00PM UroGen Pharma to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
Apr 27, 2025 04:00PM OLYMPUS Long-Term Follow-Up Study Reports Nearly Four-Year Duration of Response in Subset of Patients with Low-Grade Upper Tract Urothelial Cancer Who Achieved a Complete Response to Initial JELMYTO T
Apr 27, 2025 01:00PM New Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Quality of Life in Patients with LG-IR-NMIBC
Apr 27, 2025 12:30PM New Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Demonstrates Median Duration of Response of Two Years in Patients with LG-IR-NMIBC
Apr 26, 2025 06:30PM UroGen Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Inva
Apr 26, 2025 10:00AM UroGen Pharma Announces Encouraging Results from a Phase 1 Dose-Escalation Study Evaluating UGN-301 in Non-Muscle Invasive Bladder Cancer
Apr 14, 2025 08:00AM UroGen Announces Data Presentations at the American Urological Association 2025 Annual Meeting Highlighting Emerging Evidence Supporting Our Portfolio for Urothelial Cancers
Mar 10, 2025 08:00AM UroGen Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102
Mar 7, 2025 08:00AM UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 27, 2025 08:00AM UroGen Pharma to Report Fourth Quarter and Full-Year 2024 Financial Results on Monday, March 10, 2025
Feb 24, 2025 04:00PM UroGen Pharma to Present at TD Cowen 45th Annual Health Care Conference
Feb 20, 2025 08:02AM UroGen Pharma (URGN) Advances Long-Term Growth Strategy by Acquiring a Next-Generation Investigational Oncolytic Virus (ICVB-1042) and Announces Multiple Strategic Research Collaborations
Feb 20, 2025 08:00AM UroGen Advances Long-Term Growth Strategy by Acquiring a Next-Generation Investigational Oncolytic Virus (ICVB-1042) and Announces Multiple Strategic Research Collaborations
Feb 14, 2025 02:30PM UroGen Pharma (URGN) Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102
Feb 14, 2025 02:30PM UroGen Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102
Feb 12, 2025 08:02AM UroGen Pharma (URGN): Data from a Long-Term Follow-up Study to the OLYMPUS Trial that Shows a Median Duration of Response of Nearly Four Years in Patients Achieving Complete Response with JELMYTO Publ
Feb 12, 2025 08:00AM Data from a Long-Term Follow-up Study to the OLYMPUS Trial that Shows a Median Duration of Response of Nearly Four Years in Patients Achieving Complete Response with JELMYTO Published in The Journal o
Jan 30, 2025 08:00AM UroGen Pharma to Present at Upcoming Investor Conferences
Jan 22, 2025 08:04AM UroGen Pharma (URGN) New Real-World Durability of Response Data for JELMYTO Reports 68% Recurrence-Free Survival Rate
Jan 22, 2025 08:00AM New Real-World Durability of Response Data for JELMYTO Reports 68% Recurrence-Free Survival Rate (RFS) at Three Years Across a Broad Patient Population with Low-Grade Upper Tract Urothelial Cancer (LG
Jan 15, 2025 08:05AM UroGen Pharma (URGN): ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months
Jan 15, 2025 08:00AM ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-App
Dec 6, 2024 08:00AM UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dec 5, 2024 03:31PM UroGen Pharma (URGN) Presents Data from Long-Term Follow-up Study to the OLYMPUS Trial
Dec 5, 2024 03:30PM Long-Term Follow-up Study to the OLYMPUS Trial Presented at SUO 2024 Reports Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®
Dec 5, 2024 03:22PM UroGen Pharma (URGN): UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial
Dec 5, 2024 03:15PM UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBC
Dec 2, 2024 08:00AM UroGen Announces New Data Presentations at the Society of Urologic Oncology 2024 Annual Meeting Highlighting Urothelial Cancer Portfolio Aimed at Addressing Unmet Needs
Nov 26, 2024 08:02AM UroGen Pharma (URGN) Reports New Data from a Long-Term Follow-up Study to the OLYMPUS Trial Show Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO
View Older Stories